Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Ionis Pharma reports strong pipeline progress and commercial success

Ionis Pharma's Q3 earnings call highlighted positive pipeline developments, successful product launches, and sustained investment for growth.
While facing challenges in competitive positioning and data availability, Ionis Pharma remains focused on leveraging opportunities in patient engagement and market expansion.
Overall, Ionis Pharma's performance reflects a promising outlook with strong potential for future growth and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients Ionis plans to independently bring donidalorsen to U.S. patients if approved Donidalorsen Phase 3 results expected in the first half of 2024 CARLSBAD, Calif. , Dec. 18, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd.

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

CARLSBAD, Calif. , Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors.

Ionis announces the appointment of Michael Yang to Board of Directors

Ionis Pharmaceuticals is focused on developing and strengthening its position in the oligonucleotide therapeutics sector. Oligonucleotide therapeutics offer a novel method for treating diseases by altering gene expression and targeting specific genes or genetic sequences. Ionis Pharmaceuticals has a pipeline of potential commercial medicines, including Eplontersen, Olezarsen, and Donidalorsen, which have shown promising results in clinical trials.

Ionis Pharmaceuticals: Pioneering Precision Medicine

Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.

Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise

Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part 2, the long-term extension portion of the study Encouraging EEG and clinical observations support continued development MIAMI , Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 (BIIB121) in Angelman syndrome. ION582 was generally well tolerated in the study and showed encouraging electroencephalogram (EEG) activity trends and early signals of positive clinical improvement, which will need to be confirmed upon analysis of the full data set in mid-2024.

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome

Continued treatment over two years with donidalorsen demonstrated sustained reduction in hereditary angioedema attacks and improved quality of life Donidalorsen recently received orphan drug designation in the U.S. Topline Phase 3 results expected in H1 2024 CARLSBAD, Calif. , Nov. 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from an ongoing Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational prophylactic medicine, donidalorsen, in patients with hereditary angioedema (HAE), a rare and life-threatening genetic disease.

Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates.

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice President, Investor Relations Brett Monia - Chief Executive Officer Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Richard Geary - Chief Development Officer Beth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Development Officer Conference Call Participants Gary Nachman - Raymond James Luca Issi - RBC Capital Yale Jen - Laidlaw & Company Allison Bratzel - Piper Sandler Yanan Zhu - Wells Fargo Kostas Biliouris - BMO Capital Markets Joseph Stringer - Needle & Company Myles Minter - William Blair David Lebowitz - Citi Operator Good morning, and welcome to Ionis' Third Quarter 2023 Financial Results Conference Call. As a reminder this call is being recorded.

Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients with FCS; on track for regulatory filings in early 2024 Eplontersen marketing applications accepted for review in the EU and Canada; potential U.S. approval in December 2023 On track to achieve 2023 financial guidance CARLSBAD, Calif. , Nov. 2, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the third quarter of 2023.

Ionis reports third quarter 2023 financial results

Webcast scheduled for Thursday, November 2 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis to hold third quarter 2023 financial results webcast

With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines to patients beginning in 2024 Plan to add four new wholly owned neurology medicines to clinical pipeline by end of 2024 Innovative technology advances unlocking new opportunities in neurology and cardiology as well as in new therapeutic areas With multiple launches anticipated over the coming years, Ionis positioned for next-level value creation driven by significant revenue growth and positive cash flow Ionis to webcast Innovation Day today at 8:00 a.m. ET CARLSBAD, Calif.

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen halted disease progression and continuously improved quality of life at 35-, 66- and 85-week analyses Data demonstrates consistent and sustained benefit on all co-primary and secondary endpoints CARLSBAD, Calif. , Sept. 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that The Journal of the American Medical Association  (JAMA) published positive results from the Phase 3 NEURO-TTRansform study of eplontersen, an investigational treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit

Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.

Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs

Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.

Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%

Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?

Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by Ionis Ionis to receive a $60 million upfront payment CARLSBAD, Calif. , Sept. 27, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).

Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease

Ionis Pharmaceuticals said on Tuesday its experimental drug met main goal in a late-stage trial testing it as a treatment for a rare genetic disorder known as familial chylomicronemia syndrome.

Ionis Pharma's genetic disorder drug meets main goal in late-stage study

Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent  Olezarsen demonstrated a favorable safety and tolerability profile Ionis plans to file a New Drug Application with U.S. FDA in preparation for first potential independent launch Phase 3 studies continue evaluating olezarsen in broader patient population with severe hypertriglyceridemia (SHTG)  Ionis to host webcast today at 11 a.m. ET CARLSBAD, Calif.

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome

Goldman Sachs

Eli Lilly

Pinduoduo Inc - ADR

Peloton

T-Mobile US

Toast

While many retail investors are keen to discover which securities the big market players are snapping up, sometimes it's more telling to zero in on the stocks institutional traders are selling. Why? Because trading, for all its analytics, can be an emotional rollercoaster.

The 7 Most Hated Stocks by Institutional Traders

Ionis Innovation Day: Discovering, Developing and Delivering Transformational Medicines Presentations by key members of Ionis leadership and notable KOLs CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and analyst day on Wednesday, October 4.

Ionis to host investor and analyst day event

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?

Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially approved drugs for various diseases. Ionis has a strong pipeline of late-stage candidates, including Eplontersen, Olezarsen, and Donidalorsen, with the potential for significant market opportunities.

Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers

Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates.

Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News for Ionis Pharma Stock (IONS)